← Back to Screener
Ainos, Inc. Common Stock (AIMD)
Price$1.97
Favorite Metrics
Price vs S&P 500 (26W)-56.49%
Price vs S&P 500 (4W)24.52%
Market Capitalization$14.31M
All Metrics
Book Value / Share (Quarterly)$2.10
P/TBV (Annual)6.82x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-67.25%
Cash Flow / Share (Quarterly)$-0.97
Price vs S&P 500 (YTD)15.98%
Gross Margin (TTM)82.62%
Net Profit Margin (TTM)-9114.22%
EPS (TTM)$-4.29
10-Day Avg Trading Volume0.04M
EPS Excl Extra (TTM)$-4.29
Revenue Growth (5Y)15.70%
EPS (Annual)$-7.82
ROI (Annual)-54.02%
Gross Margin (Annual)-153.74%
Net Profit Margin (5Y Avg)-18256.66%
Cash / Share (Quarterly)$0.24
ROA (Last FY)-51.57%
Revenue Growth TTM (YoY)178.22%
EBITD / Share (TTM)$-2.57
ROE (5Y Avg)-82.86%
Operating Margin (TTM)-8574.62%
Cash Flow / Share (Annual)$-1.89
P/B Ratio1.43x
P/B Ratio (Quarterly)1.65x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)213.96x
Net Interest Coverage (TTM)-23.11x
ROA (TTM)-58.78%
EV / EBITDA (TTM)8.09x
EPS Incl Extra (Annual)$-7.82
Current Ratio (Annual)1.10x
Quick Ratio (Quarterly)2.67x
3-Month Avg Trading Volume0.45M
52-Week Price Return-27.04%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.03
P/S Ratio (Annual)690.50x
Asset Turnover (Annual)0.00x
52-Week High$4.50
Operating Margin (5Y Avg)-17417.93%
EPS Excl Extra (Annual)$-7.82
CapEx CAGR (5Y)16.36%
Tangible BV CAGR (5Y)44.57%
26-Week Price Return-47.75%
Quick Ratio (Annual)1.06x
13-Week Price Return2.82%
Total Debt / Equity (Annual)0.77x
Current Ratio (Quarterly)2.96x
Enterprise Value$24.186
Revenue / Share Growth (5Y)23.46%
Asset Turnover (TTM)0.00x
Book Value / Share Growth (5Y)75.14%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)0.34x
Pretax Margin (Annual)-71694.93%
Cash / Share (Annual)$1.26
3-Month Return Std Dev102.92%
Gross Margin (5Y Avg)-40.40%
Net Income / Employee (TTM)$-0
ROE (Last FY)-95.79%
Net Interest Coverage (Annual)-19.79x
EPS Basic Excl Extra (Annual)$-7.82
P/FCF (TTM)95.43x
Receivables Turnover (TTM)3768.00x
Total Debt / Equity (Quarterly)1.10x
EPS Incl Extra (TTM)$-4.29
ROI (TTM)-62.24%
P/S Ratio (TTM)126.63x
Pretax Margin (5Y Avg)-18255.75%
Revenue / Share (Annual)$0.01
Tangible BV / Share (Annual)$0.09
Price vs S&P 500 (52W)-62.13%
Year-to-Date Return20.12%
5-Day Price Return20.12%
EPS Normalized (Annual)$-7.82
ROA (5Y Avg)-139.96%
Net Profit Margin (Annual)-71698.79%
Month-to-Date Return41.73%
Cash Flow / Share (TTM)$-0.25
EBITD / Share (Annual)$-4.97
Operating Margin (Annual)-68098.55%
LT Debt / Equity (Annual)0.58x
ROI (5Y Avg)-54.92%
LT Debt / Equity (Quarterly)1.10x
EPS Basic Excl Extra (TTM)$-4.29
P/TBV (Quarterly)26.79x
P/B Ratio (Annual)0.41x
Inventory Turnover (TTM)0.12x
Pretax Margin (TTM)-9114.22%
Book Value / Share (Annual)$5.03
Price vs S&P 500 (13W)-0.05%
Beta2.43x
Revenue / Share (TTM)$0.02
ROE (TTM)-119.35%
52-Week Low$1.26
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
AIMDAinos, Inc. Common Stock | 126.63x | 178.22% | 82.62% | — | $1.97 |
LLYEli Lilly & Co. | 13.44x | 44.70% | 83.04% | 27.59% | $927.03 |
JNJJohnson & Johnson | 5.85x | 7.87% | 67.95% | 14.90% | $234.18 |
ABBVABBVIE INC. | 6.03x | 8.57% | 71.62% | -2.88% | $208.38 |
MRKMerck & Co., Inc. | 4.53x | 1.31% | 78.55% | 21.23% | $119.07 |
AZNAstraZeneca PLC | 5.30x | 8.63% | 81.31% | 21.88% | $204.80 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $151.97 |
NVONovo-Nordisk A/S | 3.70x | 6.43% | 80.98% | 20.66% | $40.52 |
ABTAbbott Laboratories | 3.74x | 6.59% | 56.50% | 8.20% | $96.81 |
PFEPfizer Inc. | 2.51x | -1.64% | 75.81% | -3.51% | $27.56 |
BMYBristol-Myers Squibb Co. | 2.55x | -0.22% | 72.63% | — | $60.17 |
About
Ainos Inc combines artificial intelligence with biotech development across two distinct platforms. Its AI division creates sensing technology that digitizes scent data for applications in robotics, manufacturing, and healthcare, while its biotech unit develops oral interferon therapeutics for rare, autoimmune, and infectious diseases. The dual-platform approach targets multiple markets in emerging sensory technology and specialized pharmaceuticals.